Article Text

Download PDFPDF

HLA-G-specific microRNAs a novel approach for targeting tumors
  1. Simon Jasinski-Bergner1,
  2. Arndt Hartmann2,
  3. Verena Spath2,
  4. Stefan Huettelmaier3,
  5. Juliane Braun3,
  6. Juergen Bukur1 and
  7. Barbara Seliger1
  1. Aff1 grid.9018.00000000106792801Martin Luther University Halle-Wittenberg, Institute of Medical Immunology Halle Germany
  2. Aff2 grid.5330.50000000121073311University of Erlangen, Institute of Pathology Erlangen Germany
  3. Aff3 grid.9018.00000000106792801Martin Luther University Halle-Wittenberg, Institute of Molecular Medicine Halle Germany

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Immune inhibitory molecules on immune cells as well as on tumor cells appear to play a key role in modulating the immunogenicity of tumors and the efficacy of immunotherapies. One mediator is represented by the non-classical HLA-G antigen, which is often overexpressed in human tumors when compared to corresponding normal tissues thereby inhibiting both innate as well as adaptive immune responses. Since discordant HLA-G transcript and protein expression levels were often found in tumors of distinct origin posttranscriptional control mechanisms have been recently suggested. Indeed, different HLA-G-specific miRs have been identified, which were able to downregulate HLA-G surface expression. The miR-mediated inhibition of HLA-G enhanced the NK cell recognition. These miRs were also differentially expressed in renal cell carcinoma (RCC) versus normal kidney epithelium. Immunohistochemical analysis demonstrated of a high frequency HLA-G expression in RCC lesions, which was associated with disease progression and inversely correlated with the expression of HLA-G-specific miRs. These data postulate that HLA-G-specific miRs might be used as prognostic markers as well as potential therapeutics for targeting HLA-G expressing RCC.